PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 20, 2011Journal of Clinical Oncology14 citations

Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.

View Full Paper
MDMeletios Α. DimopoulosRORobert Z. OrlowskiRNRubén Niesvizky

Key Points

Key points are not available for this paper at this time.

Abstract

8009

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dimopoulos et al. (2011) studied this question.

synapsesocial.com/papers/6a1a7cc17ff99bba0645c116https://doi.org/10.1200/jco.2011.29.15_suppl.8009
Ask AI
Helpful
Bookmark
Share
View Full Paper